ecancermedicalscience

Erratum

Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayeasian network meta-analysis

12 Oct 2021
Victor Hugo Fonseca de Jesus, Rachel P Riechelmann

Throughout the text, please consider that the primary outcome of the PRODIGE24 trial was disease-free survival, and not overall survival.

Related Articles

Liudmila Castelo David, Teresa Mota Garcia, Isaulina Barreto, Esperança Carvalho, Laurinda Barreto, Clara Aleydis, Laurinda Coelho, Lúcio Lara Santos
Ajay Kumar Yadav, Anshuman Pandey, Rahul Singh, Hareesh Shanthappa Nellikoppad, Bhanu Pratap Singh
Ally H Mwanga, Jeanine Justiniano, Eric M Mbuguje, Balowa Musa, Deogratius B Mwanakulya, Andrew Swallow, Edith Kimambo, Eva Uiso, Swaleh Pazi, Latifa Rajab, Nashivai E Kivuyo, Larry Akoko, Azza Naif, Advera Ngaiza, Sara Nyagabona, Jerry Ndumbalo, Amos R Mwakigonja, Jim E Littlejohn, Seif Wibonela, Cameron E Gaskill
Dario Cattel, Rosario De Feo, Francesco Sabbatino, Stefano Pepe, Alessandro Puzziello